What Espasmo Antalgina Treats: Main Uses and Benefits

This combination is commonly used to help with symptoms related to physical discomfort caused by the involuntary muscle contractions. It is applied across therapeutic domains like the gastrointestinal, biliary, and genitourinary tracts. It is relevant for easing symptoms associated with acute or disruptive episodes, such as intestinal colic, painful stomach cramps, renal colic (kidney stones), and dysmenorrhoea (menstrual cramps). The antispasmodic component helps relieve discomfort caused by spasms in the stomach, intestines, kidney, and bladder.

The medication may assist with easing symptoms that interfere with daily comfort during phases when symptoms become more noticeable, providing supportive relief when symptoms interfere with routine activities. It is also used for managing fever that may accompany the acute spasmodic pain, contributing to easing the overall symptom load.

“The combination is considered relevant in contexts marked by increased discomfort or tension where the symptoms are linked to heightened physiological activity.”

Quick Fact: Relief for Visceral Spasm and Severe Colicky Pain

Eligibility and Contraindicated Populations

The eligibility profile for Espasmo Antalgina is defined by absolute prohibitions and restrictions established in official regulatory documents. Use is strictly contraindicated for patients with a known hypersensitivity to Hyoscine Butylbromide, Sodium Metamizole, or other pyrazolone compounds.

Absolute Non-Eligibility: The medicine must not be used by individuals with certain serious pre-existing conditions, including myasthenia gravis, untreated narrow-angle glaucoma, and disorders of the haematopoietic system, such as a history of agranulocytosis. It is also prohibited in cases of mechanical stenosis in the gastrointestinal or genitourinary tracts, paralytic ileus, and megacolon.

Age and Reproductive Stage Restrictions: The drug is contraindicated in infants below three months or five kilograms of body weight. For adults, use is restricted by reproductive stage: it is contraindicated during the third trimester of pregnancy and is generally not recommended during the first two trimesters or while breastfeeding (milk must be discarded for a regulatory period following use). The standard fixed-dose formulation is typically not recommended for children under 15 years.

Conditional Use: Caution is required for patients with severe renal or hepatic impairment, and those susceptible to tachyarrhythmia or urinary outlet obstructions.

Interactions with other medicines and products

This medication, a fixed combination of Hyoscine Butylbromide and Sodium Metamizole, has formally documented interaction patterns primarily concerning its two active ingredients. The profile includes combinations that are prohibited, interactions that modify exposure levels, and those resulting in additive pharmacodynamic effects.

Official Interaction Statements

• Co-administration with anticholinergic agents, including tri- and tetracyclic antidepressants and antihistamines, leads to the officially documented intensification of the anticholinergic effect.
• The Metamizole component is a documented enzyme inducer, causing a reduction in the plasma concentration and systemic exposure of co-administered sensitive CYP substrates such as Cyclosporine, Methadone, and Valproic acid.
• The use of Glucocorticoids alongside this medicine increases the documented risk of gastro-intestinal bleeding.
• The diuretic effect of Furosemide is officially stated as attenuated when co-administered.
• Co-administration with Neuroleptics, particularly Phenothiazine derivatives, is officially noted to carry a risk of severe hypothermia.
• The antiplatelet effect of low-dose Acetylsalicylic acid is documented as being inhibited when the drugs are taken simultaneously.

Regulatory Restrictions

The physiological effects of Espasmo Antalgina result from the combined action of its two components on distinct regulatory systems. The spasmolytic component, Hyoscine Butylbromide, acts as a competitive antagonist at peripheral Muscarinic Acetylcholine Receptors ( M1, M2, M3) located on visceral smooth muscle. This blockade prevents acetylcholine binding and interrupts the signal cascade that typically mobilizes Ca^2+ ions, resulting in a reduction of muscle tone and smooth muscle relaxation. Concurrently, the analgesic component, Sodium Metamizole (via its metabolites), modulates nociceptive signaling primarily within the central nervous system. This is achieved through the inhibition of COX enzymes, hypothesized to involve COX-3, and the engagement of inhibitory pathways such as the Cannabinoid Receptor Type 1 ( CB1). The metabolites elevate the central threshold for pain perception and modulate the intensity of nociceptive signals. This dual-level action engages both the motor component (contraction) and the sensory component (perception) of the signal-contraction cycle.

Espasmo Antalgina is a fixed-dose combination product containing the antispasmodic Pituifenone and the analgesic Metamizole (also known as Dipyrone). Since the regulatory details for the specific combination product may vary by country, the general administration guidelines for the key active component, Metamizole, provide the foundation for correct usage.

Metamizole Component (Basis for Use)

Procedural Structure

The administration of Espasmo Antalgina must strictly follow the dosing parameters established by the relevant national drug authority.

• Verification: Confirm the exact formulation (e.g., tablet strength, concentration) and the recommended age/weight group before administration.
• Dosing: Measure or count the lowest effective single dose, ensuring the total amount does not exceed the maximum daily limit (e.g., 4,000 mg of Metamizole component for adults).
• Timing: Administer doses with appropriate time spacing to maintain therapeutic effect without surpassing the maximum allowable frequency or amount.
• Adjustments: Dose adjustments for pediatric patients must be strictly calculated according to body weight to prevent potential toxicity.

This medicine should only be used as directed by a healthcare professional and solely for the duration prescribed. These instructions reflect the regulatory constraints on safe dosage and administration and do not address the clinical reasons for its use.

Espasmo Antalgina: Recent Clinical Evidence

This section provides an overview of clinical research concerning the combination of Dipyrone (Metamizole) and Hyoscine Butylbromide (N-Butylscopolamine), the two active components of this formulation. This information summarizes research findings and is not a recommendation for use or a substitute for medical advice.

Combination Studies and Therapeutic Focus

Clinical trials focusing on the combination of Dipyrone and Hyoscine Butylbromide primarily evaluate their effects on acute visceral pain, which is pain originating from internal organs. The research aims to assess the simultaneous activity of the two components:

• Dipyrone (Analgesic): Investigated for its potent pain-relieving and fever-reducing properties, particularly in moderate-to-severe pain, including pain related to injury, surgery, or colic. Studies suggest its mechanism of action involves inhibiting central nervous system pathways, distinct from traditional NSAIDs.
• Hyoscine Butylbromide (Antispasmodic): Research evaluates its use in relaxing the smooth muscles of the gastrointestinal, biliary, and urinary tracts. This action is explored for its potential role in managing cramping or spasms associated with visceral pain.

Key Research Areas

Safety Consideration in Research

It is important to note that studies on Dipyrone must account for the well-documented, rare but serious risk of agranulocytosis (a severe reduction in white blood cells). Consequently, research often focuses on risk-benefit profiles and rigorous patient monitoring, particularly in populations where the drug is still legally available.

Common questions about Espasmo Antalgina (FAQ)

Q: How quickly does Espasmo Antalgina typically start working after taking it?

A: Official regulatory documents indicate that the pain-relieving effect of the medicine usually begins to act about 30 minutes after taking it orally. Official documents indicate the product is formulated for the relief of pain associated with smooth muscle spasm.

Q: What is the expected duration of the effects of Espasmo Antalgina?

A: According to the official product information, the pain-relieving effect is generally expected to last between four to six hours. This duration is based on regulatory information regarding the elimination of the analgesic component.

Q: Is Espasmo Antalgina used for stomach cramps or other types of pain?

A: The fixed combination is specifically indicated for the relief of acute pain linked to spasms. While the Metamizole component is known for treating moderate to severe pain, the combination is primarily indicated for pain related to involuntary smooth muscle movement, such as spasms.

Q: What kind of spasms is Espasmo Antalgina primarily intended to address?

A: Official documents state the medicine is primarily indicated for spasms affecting the smooth muscles of internal organs, including the gastrointestinal, biliary (gallbladder), and urinary tracts.

Q: Can Espasmo Antalgina be used for headaches or only for cramps?

A: The combination product is primarily indicated for acute pain associated with smooth muscle spasm, such as cramping. While the pain-relieving ingredient, Metamizole, may be used for various types of moderate pain, this specific fixed combination’s indication focuses on spasm-associated visceral pain.

Q: What is the role of the antispasmodic component in the medicine?

A: The antispasmodic component, Hyoscine Butylbromide, is included to promote relaxation of the smooth muscles of internal organs. By relieving the spasm, its role is to promote relaxation, which helps relieve the resulting pain.

Q: What is the difference in effect if Espasmo Antalgina is taken with food versus without?

A: Official regulatory data suggests that taking the medication with food may slightly delay the onset of the pain-relieving effect. While the active ingredients are generally absorbed when taken orally, consumption with food may influence the speed at which the medication begins working.

Q: Is there a known interaction between Espasmo Antalgina and alcohol?

A: Official regulatory labeling cautions against or prohibits the consumption of alcohol when using Metamizole products. This is advised due to the possibility of an acute reaction, such as facial flushing and nausea, and the documented potential for enhanced effects of alcohol.

Q: Is there any information available on its use during pregnancy (descriptive only)?

A: Official drug documents state the medicine is strictly contraindicated (prohibited) during the third trimester of pregnancy. Use during the first two trimesters is generally not recommended or used only after a risk-benefit assessment as described in regulatory documentation.

Q: Are there any specific details about its use in pediatric patients?

A: Regulatory documents state the medicine is contraindicated for infants under three months or five kilograms of body weight. The standard fixed-dose formulation is typically not recommended for children under 15 years; dosing for younger patients is referenced in regulatory documents as requiring calculation based on body weight.

Q: Does taking Espasmo Antalgina affect blood pressure?

A: Official documentation lists hypotension (low blood pressure) and tachycardia (increased heart rate) as possible adverse effects. These effects are documented in the official safety profile, particularly following injection but also with oral use.

Q: What does the available clinical evidence show about its primary use?

A: The overall body of research summarized in official documents indicates that the primary function of this combination is the rapid and comprehensive relief of acute visceral pain coupled with involuntary smooth muscle spasm. Studies evaluate both the pain reduction and the degree of spasm relief.

Q: Can this medication affect a person's alertness or focus?

A: Official guidance advises caution because the product may cause effects such as dizziness and accommodation disorders (visual disturbances). Regulatory guidance advises caution because these effects may impair attention, which can affect the ability to drive or operate machinery.

Q: Is it common for people to experience sleep disturbances while taking it?

A: While not explicitly listed as 'sleep disturbances,' official safety information includes somnolence (drowsiness) and other effects related to the central nervous system. These documented effects may indirectly influence a person's sleep patterns.

Q: Why do some people experience a color change in urine after taking this medicine?

A: Regulatory documents state that a harmless red coloration of the urine can occur. This is not due to blood, but is a documented and expected effect caused by a metabolite (breakdown product) of the Sodium Metamizole component.

Q: Are there any reported interactions with over-the-counter cold and flu medicines?

A: The official product information warns against using the medicine with other anticholinergic agents, which are often found in certain over-the-counter cold and flu preparations. This combination can intensify the side effects of the antispasmodic component.

Q: Can Espasmo Antalgina affect the results of laboratory tests?

A: Yes, official documentation states that the medicine can potentially interfere with certain common laboratory tests. These tests include those that measure creatinine, triglycerides, cholesterol, and uric acid concentrations.

Q: Is Espasmo Antalgina typically available over-the-counter in certain regions?

A: The regulatory status of the key ingredient, Metamizole, varies widely across the globe. It is banned or restricted in several countries (like the US and UK) but is available for purchase without a prescription in many others, including regions of Latin America and Europe.

Q: Do any official drug labels discuss dependency concerns with Espasmo Antalgina?

A: Official regulatory documents indicate that the Metamizole component is classified as a non-narcotic analgesic. The active components do not have the central nervous system activity that is typically associated with abuse or dependence.

Q: Is Espasmo Antalgina sometimes used for gallbladder or kidney stone pain?

A: Yes, the medicine is officially indicated for the relief of pain associated with biliary colic (pain from the gallbladder) and renal colic (pain related to kidney stones). This reflects its intended use for acute, spasm-related visceral pain.

Q: Is there a maximum recommended duration of use described in the package insert?

A: Regulatory notes emphasize that treatment should generally be as short as possible and should not involve prolonged use. This recommendation is related to the need to minimize the potential for rare but serious adverse reactions associated with the Metamizole component.

Q: What does the regulatory information mention about storage temperature?

A: Official documents define specific storage requirements. The tablet form is required to be stored below 25 C. Additionally, the solution for injection must not be refrigerated or frozen.

Q: How does the paracetamol component (if present) compare to a standalone paracetamol drug?

A: This medicine does not contain Paracetamol (Acetaminophen). It is a combination of Hyoscine Butylbromide and Sodium Metamizole (Dipyrone). Metamizole is a chemically distinct analgesic and should not be mistaken for Paracetamol.

Q: Why does the drug name use the term 'Espasmo'?

A: The term 'Espasmo' is a direct reference to the function of one of the active ingredients, the antispasmodic component (Hyoscine Butylbromide). This ingredient is included in the fixed combination to specifically treat involuntary smooth muscle spasms.

Storage and Disposal Requirements

Official regulatory documents define mandatory conditions for the storage, protection, and disposal of this medicine.